ARL4C and colorectal carcinoma: A significant difference in OS was not found between CRC patients in the ARL4C-high expression group [median OS: 23 (range; 17.5–33.5) months] and ARL4C-low expression group [median OS: 32 (range; 12.75–45.5) months] (log-rank test, P = 0.6921).